VIP is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
VIP (Vasoactive Intestinal Peptide) is researched primarily for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement. The only peptide addressing vasodilation, bronchoprotection, AND neuroprotection through a single receptor family — but its 2-minute half-life makes practical delivery the primary challenge. It belongs to the Neuropeptide, vasodilator, anti-inflammatory category of compounds.
What Is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues.
The only peptide addressing vasodilation, bronchoprotection, AND neuroprotection through a single receptor family — but its 2-minute half-life makes practical delivery the primary challenge. It has attracted significant research interest for its potential effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
How Does VIP Produce These Benefits?
Activates VPAC1 and VPAC2 class B G protein-coupled receptors, initiating adenylyl cyclase-cAMP cascade and CREB phosphorylation. Drives smooth muscle relaxation via calcium channel modulation, vasodilation through nitric oxide and prostacyclin production, neuroprotection via anti-inflammatory IL-10 induction, and enhanced insulin secretion via VPAC2 signaling.
This multi-pathway activity is why VIP shows potential across several different applications rather than being limited to a single use case.
Can VIP Help With Vasodilation?
Research suggests VIP may support vasodilation through its neuropeptide, vasodilator, anti-inflammatory activity. Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
Protocols targeting vasodilation typically use 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) for ongoing continuous therapy.
Can VIP Help With Bronchodilation?
Research suggests VIP may support bronchodilation through its neuropeptide, vasodilator, anti-inflammatory activity. Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
Protocols targeting bronchodilation typically use 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) for ongoing continuous therapy.
Can VIP Help With Anti-Inflammatory Effects?
Research suggests VIP may support anti-inflammatory effects through its neuropeptide, vasodilator, anti-inflammatory activity. Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
Protocols targeting anti-inflammatory effects typically use 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) for ongoing continuous therapy.
Can VIP Help With Neuroprotection?
Research suggests VIP may support neuroprotection through its neuropeptide, vasodilator, anti-inflammatory activity. Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
Protocols targeting neuroprotection typically use 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) for ongoing continuous therapy.
Can VIP Help With Lung Function Improvement?
Research suggests VIP may support lung function improvement through its neuropeptide, vasodilator, anti-inflammatory activity. Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
Protocols targeting lung function improvement typically use 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) for ongoing continuous therapy.
Can Stacking Enhance VIP Benefits?
Combines with inhaled corticosteroids or bronchodilators for synergistic airway relaxation in asthma/COPD.
See our VIP stacking guide for detailed combination protocols.
What Is the Bottom Line on VIP Benefits?
VIP is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement. The evidence base includes: Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
VIP is not fda-approved. orphan drug designation for pulmonary hypertension. fda announced plans to remove from compounding lists. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
VIP : Benefits, Dosage, Side Effects & Research
Related Reading
- VIP Dosage Guide
- VIP Side Effects
- VIP Stacking Guide
- VIP Cycle Guide
- VIP Research
- Dihexa Complete Guide
Calculate Your VIP Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for VIP.
Open Calculator →Research-Grade Sourcing
If you're going to research VIP, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues. It is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What is the recommended VIP dosage?
Common dosages: 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation. Cycle length: ongoing continuous therapy. Half-life: 2 minutes (extremely short). Use our peptide calculator for exact reconstitution math.
What are the side effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Is VIP safe?
VIP has shown a favorable safety profile in research. Not FDA-approved. Orphan drug designation for pulmonary hypertension. FDA announced plans to remove from compounding lists. All research should follow appropriate safety protocols.